[go: up one dir, main page]

RU2361860C2 - Новые замещенные 3-сера-индолы - Google Patents

Новые замещенные 3-сера-индолы Download PDF

Info

Publication number
RU2361860C2
RU2361860C2 RU2005137403/04A RU2005137403A RU2361860C2 RU 2361860 C2 RU2361860 C2 RU 2361860C2 RU 2005137403/04 A RU2005137403/04 A RU 2005137403/04A RU 2005137403 A RU2005137403 A RU 2005137403A RU 2361860 C2 RU2361860 C2 RU 2361860C2
Authority
RU
Russia
Prior art keywords
indole
thio
methyl
acetic acid
methylsulfonyl
Prior art date
Application number
RU2005137403/04A
Other languages
English (en)
Other versions
RU2005137403A (ru
Inventor
Роджер БОННЕРТ (GB)
Роджер Боннерт
Раксана РАСУЛ (GB)
Раксана РАСУЛ
Original Assignee
Астразенека Аб
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Астразенека Аб filed Critical Астразенека Аб
Publication of RU2005137403A publication Critical patent/RU2005137403A/ru
Application granted granted Critical
Publication of RU2361860C2 publication Critical patent/RU2361860C2/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Изобретение относится к новым замещенным 3-сера-индолам формулы I: ! ! или его фармацевтически приемлемым солям, либо их сольватам ! где R1 означает NR4СOR6, NHSO2R5, NHCOR6, 5-6-членный гетероарил, содержащий 1-2 гетероатома, независимо выбранные из N, S и О; ! R2 означает Н, С1-7алкил; R3 означает хинолил, фенил, причем последний замещен галогеном, C1-6алкокси, SO2R4; ! R4 означает C1-6алкил; ! R5 и R6 независимо означают С1-6алкил, фенил, имидазолил, все из которых могут быть замещены NR14R15; ! R14, R15 каждый независимо означает Н, C1-С6алкил; при условии, что если R1 означает NHSO2R5, то R3 не означает фенил. ! Соединения могут быть использованы для производства лекарства для применения в лечении астмы, ринита или ХОБЛ. 5 н. и 5 з.п. ф-лы.

Description

Текст описания приведен в факсимильном виде.
Figure 00000001
Figure 00000002
Figure 00000003
Figure 00000004
Figure 00000005
Figure 00000006
Figure 00000007
Figure 00000008
Figure 00000009
Figure 00000010
Figure 00000011
Figure 00000012
Figure 00000013
Figure 00000014
Figure 00000015
Figure 00000016
Figure 00000017
Figure 00000018
Figure 00000019
Figure 00000020
Figure 00000021
Figure 00000022
Figure 00000023
Figure 00000024
Figure 00000025
Figure 00000026
Figure 00000027
Figure 00000028
Figure 00000029
Figure 00000030
Figure 00000031
Figure 00000032
Figure 00000033
Figure 00000034
Figure 00000035
Figure 00000036
Figure 00000037
Figure 00000038
Figure 00000039
Figure 00000040
Figure 00000041
Figure 00000042
Figure 00000043
Figure 00000044
Figure 00000045
Figure 00000046
Figure 00000047
Figure 00000048
Figure 00000049
Figure 00000050
Figure 00000051
Figure 00000052
Figure 00000053
Figure 00000054
Figure 00000055
Figure 00000056
Figure 00000057
Figure 00000058
Figure 00000059
Figure 00000060
Figure 00000061
Figure 00000062
Figure 00000063
Figure 00000064
Figure 00000065
Figure 00000066
Figure 00000067

Claims (10)

1. Соединение формулы (I) или его фармацевтически приемлемая соль либо их сольват
Figure 00000068

где R1 представляет собой NR4COR6, NHSO2R5, NHCOR6 или 5-6-членную гетероароматическую группу, содержащую 1-2 гетероатома, независимо выбранные из N, S и О;
R2 представляет собой водород или С1-7алкил;
R3 представляет собой хинолил или фенил, причем последний возможно замещен галогеном, C1-6алкокси или SO2R4;
R4 представляет собой С1-6алкил;
R5 и R6 независимо представляют собой С1-6алкильную группу, фенил, имидазолил, все из которых могут быть возможно замещены NR14R15; и
каждый из R14 и R15 независимо представляет собой атом водорода или C1-С6алкил;
при условии, что если R1 представляет собой NHSO2R5, то R3 не представляет собой фенил.
2. Соединение по п.1, где R1 представляет собой NHCOMe.
3. Соединение по п.1 или 2, где R2 представляет собой С1-6алкил.
4. Соединение по п.3, где R3 представляет собой фенил, возможно замещенный галогеном или метилсульфоном.
5. Соединение по п.1, выбранное из:
4-(ацетиламино)-3-[(4-хлорфенил)тио]-2-метил-1Н-индол-1-уксусной кислоты;
3-[(4-хлорфенил)тио]-2-метил-4-[(метилсульфонил)амино]-1Н-индол-1-уксусной кислоты;
3-[(4-хлорфенил)тио]-2-метил-4-(5-пиримидинил)-1Н-индол-1-уксусной кислоты;
3-[(4-хлорфенил)тио]-2-метил-4-пиразинил-1Н-индол-1-уксусной кислоты;
3-[(2-хлорфенил)тио]-2-метил-5-[(метилсульфонил)амино]-1Н-индол-1-уксусной кислоты;
3-[(3-хлорфенил)тио]-2-метил-5-[(метилсульфонил)амино]-1Н-индол-1-уксусной кислоты;
3-[(4-хлорфенил)тио]-2-метил-5-[(метилсульфонил)амино]-1Н-индол-1-уксусной кислоты;
3-[(3-метоксифенил)тио]-2-метил-5-[(метилсульфонил)амино]-1Н-индол-1-уксусной кислоты;
3-[(4-метоксифенил)тио]-2-метил-5-[(метилсульфонил)амино]-1Н-индол-1-уксусной кислоты;
3-[(8-хинолинил)тио]-2-метил-5-[(метилсульфонил)амино]-1Н-индол-1-уксусной кислоты;
5-(ацетиламино)-3-[(4-хлорфенил)тио]-2-метил-1Н-индол-1-уксусной кислоты;
4-(ацетилэтиламино)-3-[(4-хлорфенил)тио]-2-метил-1Н-индол-1-уксусной кислоты;
3-[(4-хлорфенил)тио]-4-[(циклопропилкарбонил)амино]-2-метил-1Н-индол-1-уксусной кислоты;
4-(бензоиламино)-3-[(4-хлорфенил)тио]-2-метил-1Н-индол-1-уксусной кислоты;
4-(ацетиламино)-3-[(3-хлорфенил)тио]-2-метил-1Н-индол-1-уксусной кислоты;
3-[(4-хлорфенил)тио]-2-метил-4-[[(1-метил-1H-имидазол-4-ил)сульфонил]амино]-1Н-индол-1-уксусной кислоты;
3-[(4-хлорфенил)тио]-4-[[(диметиламино)ацетил]амино]-2-метил-1Н-индол-1-уксусной кислоты;
4-(ацетиламино)-2-метил-3-[[4-(метилсульфонил)фенил]тио]-1Н-индол-1-уксусной кислоты;
4-(ацетиламино)-3-[(2-хлорфенил)тио]-2-метил-1Н-индол-1-уксусной кислоты;
4-(ацетиламино)-2-метил-3-[[4-(этилсульфонил)фенил]тио]-1Н-индол-1-уксусной кислоты;
3-[[4-(метилсульфонил)фенил]тио]-4-(5-пиримидинил)-1Н-индол-1-уксусной кислоты;
2-метил-3-[[4-(метилсульфонил)фенил]тио]-4-(2-тиофенил)-1Н-индол-1-уксусной кислоты;
4-(3,5-диметил-4-изоксазолил)-2-метил-3-[[4-(метилсульфонил)фенил]тио]-1H-индол-1-уксусной кислоты;
4-(3-фуранил)-2-метил-3-[[4-(метилсульфонил)фенил]тио]-1Н-индол-1-уксусной кислоты;
2-метил-4-[(метилсульфонил)амино]-3-[[4-(метилсульфонил)фенил]тио]-1Н-индол-1-уксусной кислоты;
2-метил-5-[(метилсульфонил)амино]-3-[[3-(метилсульфонил)фенил]тио]-1Н-индол-1-уксусной кислоты;
2-метил-5-[(метилсульфонил)амино]-3-[[2-(метилсульфонил)фенил]тио]-1Н-индол-1-уксусной кислоты;
2-метил-3-[[4-(метилсульфонил)фенил]тио]-5-(5-пиримидинил)-1Н-индол-1-уксусной кислоты;
2-метил-3-[[4-(метилсульфонил)фенил]тио]-5-(2-тиофенил)-1Н-индол-1-уксусной кислоты;
5-(3,5-диметил-4-изоксазолил)-2-метил-3-[[4-(метилсульфонил)фенил]тио]-1Н-индол-1-уксусной кислоты;
2-метил-3-[[4-(метилсульфонил)фенил]тио]-5-(3-пиридинил)-1Н-индол-1-уксусной кислоты;
2-метил-3-[[4-(метилсульфонил)фенил]тио]-5-(1Н-пиразол-4-ил)-1Н-индол-1-уксусной кислоты;
и их фармацевтически приемлемых солей и сольватов.
6. Соединение формулы (I) или его фармацевтически приемлемая соль по любому из пп.1-5 для применения в лечении астмы, ринита или хронической обструктивной болезни легких (ХОБЛ).
7. Способ лечения астмы, ринита или ХОБЛ, включающий введение пациенту терапевтически эффективного количества соединения формулы (I) или его фармацевтически приемлемой соли, как они определены в любом из пп.1-5.
8. Применение соединения формулы (I) или его фармацевтически приемлемой соли, как они определены в любом из пп.1-5, в производстве лекарства для применения в лечении астмы, ринита или ХОБЛ.
9. Соединение формулы (I), представляющее собой 4-(ацетиламино)-3-[(4-хлорфенил)тио]-2-метил-1Н-индол-1-уксусную кислоту или ее фармацевтически приемлемую соль.
10. Применение 4-(ацетиламино)-3-[(4-хлорфенил)тио]-2-метил-1 Н-индол-1-уксусной кислоты или ее фармацевтически приемлемой соли в производстве лекарства для применения в лечении астмы, ринита или ХОБЛ.
RU2005137403/04A 2003-05-27 2004-05-25 Новые замещенные 3-сера-индолы RU2361860C2 (ru)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
SE0301569-0 2003-05-27
SE0301569A SE0301569D0 (sv) 2003-05-27 2003-05-27 Novel compounds
SE0302305A SE0302305D0 (sv) 2003-05-27 2003-08-27 Novel Compounds
SE0302305-8 2003-08-27

Publications (2)

Publication Number Publication Date
RU2005137403A RU2005137403A (ru) 2006-05-27
RU2361860C2 true RU2361860C2 (ru) 2009-07-20

Family

ID=33492578

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2005137403/04A RU2361860C2 (ru) 2003-05-27 2004-05-25 Новые замещенные 3-сера-индолы

Country Status (31)

Country Link
US (4) US7687535B2 (ru)
EP (3) EP2281815B1 (ru)
JP (2) JP4541361B2 (ru)
KR (3) KR101067586B1 (ru)
CN (2) CN102391171A (ru)
AR (1) AR044552A1 (ru)
AT (3) ATE425965T1 (ru)
AU (1) AU2004242624B2 (ru)
BR (1) BRPI0410711B8 (ru)
CA (1) CA2526866C (ru)
CO (1) CO5630030A2 (ru)
CY (3) CY1109104T1 (ru)
DE (2) DE602004020072D1 (ru)
DK (3) DK1656346T3 (ru)
ES (3) ES2361485T3 (ru)
HK (3) HK1090635A1 (ru)
HR (3) HRP20090281T1 (ru)
IL (4) IL171928A (ru)
IS (2) IS2722B (ru)
MX (1) MXPA05012680A (ru)
MY (1) MY144483A (ru)
NO (1) NO20056130L (ru)
NZ (1) NZ543722A (ru)
PL (3) PL1656346T3 (ru)
PT (3) PT2281815E (ru)
RU (1) RU2361860C2 (ru)
SE (2) SE0301569D0 (ru)
SI (3) SI1656346T1 (ru)
TW (2) TWI328004B (ru)
WO (1) WO2004106302A1 (ru)
ZA (1) ZA200509598B (ru)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
SE0303180D0 (sv) * 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
AU2005229356B2 (en) 2004-03-11 2011-06-09 Idorsia Pharmaceuticals Ltd Tetrahydropyridoindole derivatives
WO2006070325A2 (en) 2004-12-27 2006-07-06 Actelion Pharmaceuticals Ltd 2,3,4,9-tetrahydro-1h-carbazole derivatives as crth2 receptor antagonists
GB0500604D0 (en) * 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
DOP2006000016A (es) * 2005-01-26 2006-07-31 Aventis Pharma Inc 2-fenil-indoles como antagonistas del receptor de la prostaglandina d2.
MX2007012937A (es) 2005-04-21 2008-03-26 Serono Lab Pirazina-sulfonamidas 2,3-sustituidas.
PT1891075E (pt) 2005-05-24 2011-11-10 Merck Serono Sa Derivados espiro tricíclicos como moduladores do crth2
EP1916245B1 (en) 2005-07-22 2011-10-26 Shionogi & Co., Ltd. Indole derivative having pgd2 receptor antagonist activity
JP5064219B2 (ja) 2005-07-22 2012-10-31 塩野義製薬株式会社 Ｐｇｄ２受容体アンタゴニスト活性を有するアザインドール酸誘導体
EP2407459A1 (en) 2005-09-27 2012-01-18 Shionogi & Co., Ltd. Synthetic intermediate in the production of a sulfonamide derivative having PGD2 receptor antagonistic activity
EA015358B1 (ru) * 2005-09-30 2011-06-30 Пульмаджен Терапьютикс (Эсме) Лимитед Хинолины и их терапевтическое применение
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
EP2037967B1 (en) 2006-06-16 2016-12-07 The Trustees Of The University Of Pennsylvania Prostaglandin d2 receptor antagonists for treating androgenetic alopecia
MX2009000801A (es) * 2006-07-22 2009-02-03 Oxagen Ltd Compuestos que tienen actividad antagonista crth2.
EP2316824A1 (en) 2006-08-07 2011-05-04 Actelion Pharmaceuticals Ltd. (3-Amino-1,2,3,4-tetrahydro-9H-carbazoI-9-yl)-acetic acid derivates
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
CN102898380A (zh) * 2007-06-21 2013-01-30 艾克提麦斯医药品有限公司 一种crth2 拮抗剂的胺盐
NZ581811A (en) * 2007-06-21 2012-11-30 Actimis Pharmaceuticals Inc Particulates of the CRTH2 antagonist { 4,6-bis(dimethylamino)-2-(4-(4-(trifluoromethyl)benzamido)-benzyl)pyrimidin-5-yl} acetic acid
ES2386340T3 (es) 2007-12-14 2012-08-17 Pulmagen Therapeutics (Asthma) Limited Indoles y su uso terapéutico
US7750027B2 (en) 2008-01-18 2010-07-06 Oxagen Limited Compounds having CRTH2 antagonist activity
WO2010039982A1 (en) * 2008-10-01 2010-04-08 Ironwood Pharmaceuticals, Inc. Crth2 modulators
CA2751260A1 (en) 2009-02-12 2010-08-19 Stefano Crosignani Phenoxy acetic acid derivatives
BR112012000353B1 (pt) * 2009-07-06 2020-06-02 Astrazeneca Ab Composto de fórmula markush, uso do composto, processos de reação com agente de acetilação e processo para preparação de um composto
GB0913345D0 (en) 2009-07-31 2009-09-16 Astrazeneca Ab New combination 802
WO2011061527A1 (en) 2009-11-17 2011-05-26 Astrazeneca Ab Combinations comprising a glucocorticoid receptor modulator for the treatment of respiratory diseases
US9032565B2 (en) 2009-12-16 2015-05-19 Kohler Co. Touchless faucet assembly and method of operation
WO2011073662A1 (en) 2009-12-17 2011-06-23 Astrazeneca Ab Combination of a benzoxazinone and a further agent for treating respiratory diseases
ES2524079T3 (es) 2010-03-22 2014-12-04 Actelion Pharmaceuticals Ltd. Derivados de 3-(heteroaril-amino)-1,2,3,4-tetrahidro-9H-carbazol y su uso como moduladores del receptor de prostaglandina D2
GB201021992D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab Compound
GB201021979D0 (en) 2010-12-23 2011-02-02 Astrazeneca Ab New compound
MX338516B (es) 2011-04-14 2016-04-20 Actelion Pharmaceuticals Ltd Derivados de acido 7- (heteroaril-amino) -6, 7, 8, 9- tetrahidropirido[1,2-a] indol acetico y sus usos como modulador del receptor de prostaglandina.
CA2859284A1 (en) 2011-12-16 2013-06-20 Atopix Therapeutics Limited Combination of a crth2 antagonist and a proton pump inhibitor for the treatment of eosinophilic esophagitis
KR102205774B1 (ko) 2012-03-21 2021-01-20 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 모발 성장을 조절하는 방법 및 조성물
EP2903615B1 (en) * 2012-10-05 2021-04-07 Merck Sharp & Dohme Corp. 5-pyridin-3-yl-2,3-dihydro-1h-indole derivatives as aldosterone synthase (cyp11b2) inhibitors for the treatment of hypertension
US20140303121A1 (en) 2013-03-15 2014-10-09 Plexxikon Inc. Heterocyclic compounds and uses thereof
ES2688575T3 (es) 2013-03-15 2018-11-05 Plexxikon Inc. Compuestos heterocíclicos y sus usos
US20160194299A1 (en) * 2013-05-24 2016-07-07 The California Institute For Biomedical Research Compounds for treatment of drug resistant and persistent tuberculosis
PT3119779T (pt) 2014-03-17 2018-10-19 Idorsia Pharmaceuticals Ltd Derivados de ácido azaindol acético e sua utilização como modeladores de recetor d2 de prostaglandina
MX2016011900A (es) 2014-03-18 2016-12-05 Actelion Pharmaceuticals Ltd Derivados de acido azaindol-acetico y su uso como moduladores del receptor de prostaglandina d2.
GB201407807D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
GB201407820D0 (en) 2014-05-02 2014-06-18 Atopix Therapeutics Ltd Polymorphic form
ES2991300T3 (es) 2015-02-13 2024-12-03 Inserm Institut Nat De La Sante Et De Larecherche Medicale Antagonistas de PTGDR-1 y/o PTGDR-2 para prevenir y/o tratar lupus eritematoso sistémico
BR112018002012A2 (pt) 2015-07-30 2018-09-18 Univ Pennsylvania alelos polimórficos de nucleotídeo único de gene dp-2 humano para detecção de suscetibilidade à inibição do crescimento de cabelos por pgd2
EP3350179B1 (en) 2015-09-15 2021-01-13 Idorsia Pharmaceuticals Ltd Crystalline forms
CA3079029A1 (en) 2017-10-13 2019-04-18 Plexxikon Inc. Solid forms of a compound for modulating kinases

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
JPH0615542B2 (ja) 1986-07-22 1994-03-02 吉富製薬株式会社 ピラゾロピリジン化合物
US5095031A (en) 1990-08-20 1992-03-10 Abbott Laboratories Indole derivatives which inhibit leukotriene biosynthesis
WO1993005020A1 (en) 1991-09-06 1993-03-18 Merck & Co., Inc. Indoles as inhibitors of hiv reverse transcriptase
FR2692574B1 (fr) 1992-06-23 1995-06-23 Sanofi Elf Derives hydroxy-4 benzenethio, leur preparation ainsi que leur utilisation pour la preparation de derives aminoalkoxybenzenesulfonyles.
CA2156420A1 (en) 1993-02-24 1994-09-01 Theresa M. Williams Inhibitors of hiv reverse transcriptase
US5486525A (en) 1993-12-16 1996-01-23 Abbott Laboratories Platelet activating factor antagonists: imidazopyridine indoles
US5567711A (en) 1995-04-19 1996-10-22 Abbott Laboratories Indole-3-carbonyl and indole-3-sulfonyl derivatives as platelet activating factor antagonists
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
ATE237596T1 (de) 1996-02-13 2003-05-15 Astrazeneca Ab Chinazolinderivate und deren verwendung als vegf hemmer
PT885198E (pt) 1996-03-05 2002-06-28 Astrazeneca Ab Derivados de 4-anilinoquinazolina
TW472045B (en) 1996-09-25 2002-01-11 Astra Ab Protein kinase C inhibitor compounds, method for their preparation, pharmaceutical composition thereof and intermediate used for their preparation
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
WO1999009007A1 (en) 1997-08-21 1999-02-25 American Home Products Corporation Solid phase synthesis of 2,3-disubstituted indole compounds
JP2001526286A (ja) 1997-12-19 2001-12-18 イーライ・リリー・アンド・カンパニー 低血糖性イミダゾリン化合物
US6916841B2 (en) 1998-02-25 2005-07-12 Genetics Institute, Llc Inhibitors of phospholipase enzymes
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
WO2000078761A1 (en) 1999-06-23 2000-12-28 Sepracor, Inc. Indolyl-benzimidazole antibacterials, and methods of use thereof
AU7962200A (en) 1999-10-29 2001-05-14 Wakunaga Pharmaceutical Co., Ltd Novel indole derivatives and drugs containing the same as the active ingredient
MXPA02006338A (es) 1999-12-24 2002-12-13 Aventis Pharma Ltd Azaindoles.
AU2001258628A1 (en) 2000-05-31 2001-12-11 Astrazeneca Ab Indole derivatives with vascular damaging activity
US6878522B2 (en) * 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
CN1255391C (zh) 2000-07-07 2006-05-10 安吉奥金尼药品有限公司 作为血管破坏剂的colchinol衍生物
RU2003103603A (ru) 2000-07-07 2004-08-20 Энджиоджен Фармасьютикалз Лимитед (Gb) Производные колхинола в качестве ингибиторов ангиогенеза
JP4595182B2 (ja) * 2000-09-07 2010-12-08 ソニー株式会社 情報記録装置、情報再生装置、情報記録方法、情報再生方法、および情報記録媒体、並びにプログラム提供媒体
TWI317634B (en) 2001-12-13 2009-12-01 Nat Health Research Institutes Aroyl indoles compounds
RU2337909C2 (ru) 2002-02-01 2008-11-10 Ф.Хоффманн-Ля Рош Аг Замещенные индолы и фармацевтическая композиция, обладающая агонистической активностью в отношении альфа-1a/l адренорецептора
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
SE0200356D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
WO2003097598A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
TW200307542A (en) 2002-05-30 2003-12-16 Astrazeneca Ab Novel compounds
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) * 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
SE0202463D0 (sv) 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
SE0301569D0 (sv) 2003-05-27 2003-05-27 Astrazeneca Ab Novel compounds
SE0302232D0 (sv) 2003-08-18 2003-08-18 Astrazeneca Ab Novel Compounds
US20070232681A1 (en) 2003-10-14 2007-10-04 Oxagen Limited Compounds Having Crth2 Antagonist Activity
SE0303180D0 (sv) 2003-11-26 2003-11-26 Astrazeneca Ab Novel compounds
GB0500604D0 (en) 2005-01-13 2005-02-16 Astrazeneca Ab Novel process
GB2422831A (en) 2005-02-04 2006-08-09 Oxagen Ltd Pyrrolopyridines and their use in the treatment of diseases mediated by PGD2 at the CRTH2 receptor
US7741360B2 (en) 2006-05-26 2010-06-22 Astrazeneca Ab Bi-aryl or aryl-heteroaryl substituted indoles
JP2009539782A (ja) 2006-06-08 2009-11-19 ニューロキー エイ／エス 低体温誘導薬剤の使用方法
BRPI0713064A2 (pt) 2006-06-28 2012-07-17 Sanofi Aventis inibidores de cxcr2

Also Published As

Publication number Publication date
CA2526866C (en) 2012-10-16
CA2526866A1 (en) 2004-12-09
CN102391171A (zh) 2012-03-28
CN1795174B (zh) 2011-09-28
PL2025670T3 (pl) 2011-07-29
ATE425965T1 (de) 2009-04-15
ATE502010T1 (de) 2011-04-15
AU2004242624B2 (en) 2008-03-13
NZ543722A (en) 2007-05-31
BRPI0410711B1 (pt) 2018-09-25
MY144483A (en) 2011-09-30
IL194872A0 (en) 2011-08-01
TW200510301A (en) 2005-03-16
JP4541361B2 (ja) 2010-09-08
SE0301569D0 (sv) 2003-05-27
IL171928A (en) 2011-06-30
IS2722B (is) 2011-03-15
EP2025670B1 (en) 2011-03-16
NO20056130L (no) 2006-02-27
SE0302305D0 (sv) 2003-08-27
HK1126773A1 (ru) 2009-09-11
PT2025670E (pt) 2011-05-24
BRPI0410711A (pt) 2006-06-13
PL2281815T3 (pl) 2012-08-31
IS8189A (is) 2005-12-20
KR20110050754A (ko) 2011-05-16
IL212371A0 (en) 2011-06-30
KR101067535B1 (ko) 2011-09-27
HRP20110359T1 (hr) 2011-06-30
AR044552A1 (es) 2005-09-21
DK2281815T3 (da) 2012-06-18
DK1656346T3 (da) 2009-06-15
EP1656346A1 (en) 2006-05-17
US20090163518A1 (en) 2009-06-25
KR101067586B1 (ko) 2011-09-27
KR20110051297A (ko) 2011-05-17
PT2281815E (pt) 2012-05-24
TWI328004B (en) 2010-08-01
ES2382606T3 (es) 2012-06-11
EP2281815B1 (en) 2012-04-04
IL171928A0 (en) 2006-04-10
ES2322650T3 (es) 2009-06-24
HRP20120390T1 (hr) 2012-06-30
WO2004106302A1 (en) 2004-12-09
DE602004031894D1 (de) 2011-04-28
US20120178764A1 (en) 2012-07-12
IS8920A (is) 2010-08-09
HRP20090281T1 (en) 2009-06-30
BRPI0410711B8 (pt) 2021-05-25
CY1111469T1 (el) 2015-08-05
ZA200509598B (en) 2006-12-27
ES2361485T3 (es) 2011-06-17
HK1149563A1 (ru) 2011-10-07
DK2025670T3 (da) 2011-06-06
TW201024261A (en) 2010-07-01
US20110263614A1 (en) 2011-10-27
AU2004242624A1 (en) 2004-12-09
US20080249110A1 (en) 2008-10-09
EP2025670A1 (en) 2009-02-18
IL212265A0 (en) 2011-06-30
KR20060015303A (ko) 2006-02-16
PL1656346T3 (pl) 2009-07-31
CO5630030A2 (es) 2006-04-28
JP2010155862A (ja) 2010-07-15
EP1656346B1 (en) 2009-03-18
CY1109104T1 (el) 2014-07-02
SI2281815T1 (sl) 2012-06-29
ATE552243T1 (de) 2012-04-15
DE602004020072D1 (de) 2009-04-30
JP2007501269A (ja) 2007-01-25
US7687535B2 (en) 2010-03-30
CN1795174A (zh) 2006-06-28
SI1656346T1 (sl) 2009-08-31
HK1090635A1 (en) 2006-12-29
PT1656346E (pt) 2009-05-20
MXPA05012680A (es) 2006-02-08
SI2025670T1 (sl) 2011-06-30
EP2281815A1 (en) 2011-02-09
CY1112853T1 (el) 2016-02-10
RU2005137403A (ru) 2006-05-27

Similar Documents

Publication Publication Date Title
RU2361860C2 (ru) Новые замещенные 3-сера-индолы
RU2007101236A (ru) Новые гидантоиновые производные для лечения обструктивных заболеваний дыхательных путей
RU2455288C2 (ru) Соединения и композиции 5-(4-(галогеналкокси)фенил)пиримидин-2-амина в качестве ингибиторов киназ
RU2419624C2 (ru) Сульфонамидные производные как активаторы гликокиназы, применимые для лечения диабета типа 2
JP2021138755A5 (ru)
JP2005538955A5 (ru)
RU2458920C2 (ru) Новые соединения
RU2454415C9 (ru) Производное индола
RU2435759C2 (ru) Производные бензимидазолов и их применение для модуляции гамка-рецепторного комплекса
JP2013517283A5 (ru)
RU2004135064A (ru) Новые замещенные индолы
JP2008110984A5 (ru)
JP2008513516A5 (ru)
CA2628844A1 (en) Pyrazole derivatives and their medical use
RU2012125372A (ru) Производные пиразола в качестве ингибиторов 11-бета-hsd1
JP2007502806A5 (ru)
JP2006501295A5 (ru)
JP2011504497A5 (ru)
JP2009501745A5 (ru)
RU2012132692A (ru) Новые ингибиторы s-нитрозоглутатионредуктазы
JP2005506308A5 (ru)
RU2005136368A (ru) Производные пиперазина и их применение для лечения неврологических и психиатрических заболеваний
RU2012116877A (ru) Соединения 2-пиридона, применяемые в качестве ингибиторов нейтрофильной эластазы
RU2019136279A (ru) C5 -Анилинохиназолиновые соединения и их использование в лечении рака
RU2006129297A (ru) Производные n-(1,5-дифенил-1н-пиразол-3-ил)сульфонамида со сродством к рецепторам cb1